{"disease":{"id":"hyperammonemia","name":"Hyperammonemia","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"carglumic-acid","indication_name":"Hyperammonemia associated with N-acetylglutamate synthase deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carbaglu","generic_name":"CARGLUMIC ACID","company_name":"Recordati","drug_phase":"marketed","molecular_target":"Carbamoyl-phosphate synthase [ammonia], mitochondrial","drug_class":"Carbamoyl Phosphate Synthetase 1 Activator [EPC]","quality_score":62,"revenue":"200","mechanism":"Carbaglu works by activating the enzyme carbamoyl phosphate synthetase 1, which helps regulate ammonia levels in the body."},{"drug_id":"carbaglu","indication_name":"Hyperammonemia associated with N-acetylglutamate synthase deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Carbaglu","company_name":"Mendel Tuchman","drug_phase":"marketed","molecular_target":"Carbamoyl-phosphate synthase [ammonia], mitochondrial","drug_class":"","quality_score":27,"revenue":"200","mechanism":null},{"drug_id":"sodium-phenylacetate","indication_name":"Acute hyperammonemia and associated encephalopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SODIUM PHENYLACETATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":45,"revenue":null,"mechanism":"Sodium phenylacetate and sodium benzoate provide alternative pathways for nitrogen disposal in patients with urea cycle disorders."},{"drug_id":"sodium-benzoate","indication_name":"Hyperammonemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ammonul","generic_name":"SODIUM BENZOATE","company_name":"","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2","drug_class":"sodium benzoate","quality_score":65,"revenue":null,"mechanism":"Ammonul works by inhibiting the enzyme carbonic anhydrase 2, which helps to reduce ammonia levels in the body."},{"drug_id":"buphenyl","indication_name":"Congenital hyperammonemia, type I","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Buphenyl","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Aldose reductase, Histone deacetylase 1, Histone deacetylase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lactulose","indication_name":"Hyperammonemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cephulac","generic_name":"LACTULOSE","company_name":"Sanwa Kagaku Kenkyusho Co., Ltd.","drug_phase":"marketed","molecular_target":"","drug_class":"Osmotic Laxative [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"benzoic-acid","indication_name":"Hyperammonemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Benzeneformic Acid","generic_name":"benzoic acid","company_name":"","drug_phase":"marketed","molecular_target":"Nicotinate phosphoribosyltransferase","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":23,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":7,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT03947034","title":"Monitoring the Hyperammonaemia:TOXicity of Drugs (AmmoTOX)","phase":"","overall_status":"COMPLETED","enrollment_count":2700,"lead_sponsor_name":"Groupe Hospitalier Pitie-Salpetriere","has_results":false},{"nct_id":"NCT06178718","title":"A Phase 1 Study to Evaluate PK Profile and Food Effects on PK Parameters of TNP-2092 Capsules","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"TenNor Therapeutics (Suzhou) Limited","has_results":true},{"nct_id":"NCT06135675","title":"PK Profile and Preliminary Efficacy of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"TenNor Therapeutics (Suzhou) Limited","has_results":true},{"nct_id":"NCT05040178","title":"An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics","phase":"","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"RECORDATI GROUP","has_results":false},{"nct_id":"NCT03797222","title":"Vitamin E Supplementation in Hyperinsulinism/Hyperammonemia Syndrome","phase":"NA","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Elizabeth A Rosenfeld","has_results":true},{"nct_id":"NCT05349435","title":"A Healthy Volunteer Study to Compare Fezagepras (PBI-4050) With Sodium Phenylbutyrate","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Liminal BioSciences Ltd.","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}